Pfizer Beats Estimates, Raises Guidance on Non-Covid Growth
Pfizer topped quarterly expectations and lifted its revenue floor as core non-Covid drugs carry the load.
Pfizer just reminded the market it's more than a Covid play. The pharma giant beat quarterly estimates and raised the low end of its full-year revenue guidance — and the engine driving that upgrade isn't vaccines or antivirals. It's the rest of the portfolio doing the heavy lifting.
Here's the number you need to watch: Pfizer slashed its full-year Covid product revenue target to $4 billion, down from roughly $5 billion before. That's a $1 billion haircut on the pandemic business. And the stock is still holding up. That tells you everything about where investor confidence is shifting — away from Covid tailwinds and toward the company's broader drug lineup.
Read more S&P 500 Hits New Highs as Dow Posts Best Day in Two Months →
This is a pivot story, plain and simple. For years, bears argued Pfizer was a one-trick pony that lucked into a blockbuster vaccine cycle. A beat-and-raise quarter built on non-Covid strength punches a hole in that thesis. If the underlying business can grow without pandemic revenue propping it up, the valuation conversation changes fast.
For traders, the key question now is sustainability. One strong quarter on core products is a data point. Two is a trend. Watch the next earnings print closely to see whether management can keep lifting guidance even as Covid revenues continue to fade. The setup is interesting — but you need confirmation before loading up.
Continue reading at CNBC.
